Autism is a clinical diagnosis with lots of different underlying...

Autism is a clinical diagnosis with lots of different underlying pathological processes that can cause it. E.g. Fragile X is the most common known cause of autism. So you risk not getting a signal if your drug only treats a subset of people with autism. There is also no clear mouse model of autism either. Much better for neuren to continue with the strategy of rare diseases that can be replicated in mice with single gene edits. If neuren/NNZ-2591 is successful in all 4 phase 2 indications though then the obvious thought will be, holy sh!t, this could treat autism/lots of other things. The value wouldn’t be 4 x each individual indication but much much higher due to the thought that we have some sort of broad disease neurodevelopmental modifying compound. I don’t think it’s necessarily likely that they will have success in all 4 indications, but that would be a serious blue sky moment if they do, and I think we would get taken out at a very very high share price. AIMHO